SCHEMBL4421499

SCHEMBL4421499

OCc1cnc(Cl)cc1Nc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.39
▸ GAA P10253 2/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ ALOX15 P16050 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ CDK2 P24941 1/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ RECQL P46063 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ GLA P06280 1/20 0.38
▸ TLR8 Q9NR97 2/20 0.37
▸ WEE1 P30291 1/20 0.36
▸ BRD4 O60885 1/20 0.36
▸ BPTF Q12830 1/20 0.36
▸ KAT2B Q92831 1/20 0.36
▸ BRD9 Q9H8M2 1/20 0.36
▸ BCL6 P41182 1/20 0.36
▸ TOP2A P11388 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17119641 0.86 ADRA2A (0.42) CDK2MEN1RECQLKMT2AKDM4E
SCHEMBL17119648 0.85 KDM4E (0.40) ALDH1A1HTTCDK2MEN1MAPT
SCHEMBL29743231 0.79 KDM4E (0.49) ALDH1A1GAAMAPTKDM4ETLR8
SCHEMBL22129304 0.79 KDM4E (0.49) ALDH1A1GAAMAPTKDM4ETLR8
SCHEMBL24270834 0.76 GAA (0.50) ALDH1A1GAATDP1ALOX15HTT
SCHEMBL29492714 0.76 GAA (0.50) ALDH1A1GAATDP1ALOX15HTT
SCHEMBL21600853 0.75 MAPT (0.55) TDP1MEN1MAPTRECQLKMT2A
SCHEMBL30379619 0.75 MAPT (0.55) TDP1MEN1MAPTRECQLKMT2A
SCHEMBL1521667 0.75 PDXK (0.38) ALDH1A1MEN1RECQLKMT2AKDM4E
SCHEMBL29765350 0.75 PDXK (0.38) ALDH1A1MEN1RECQLKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 — — US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 — — US disclosed
CN-101553232-A Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS LLC (US) 2009-10-07 — — CN disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 — — EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 — — US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 ALDH1A1 1389/4885GAA 4704/4885TDP1 579/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 ALDH1A1 1389/4885GAA 4704/4885TDP1 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback